Goldman Sachs Group Significantly Increases Stake in Evotec SE to 6.12%
Summary
Goldman Sachs Group reported increasing its total stake in Evotec SE to 6.12% through instruments, signaling increased institutional interest, while MAK Capital also raised its holdings.
Key Events
-
Goldman Sachs Increases Holdings
The Goldman Sachs Group, Inc. reported increasing its total stake in Evotec SE to 6.12% as of January 13, 2026, primarily through instruments. This represents a 2.44% increase from its position on January 9, valued at approximately $14.89 million.
-
MAK Capital Increases Holdings
Michael Kaufman and MAK Capital Fund LP increased their combined stake in Evotec SE to 5.17% as of January 9, 2026, primarily through direct shareholdings. This is a net increase of 0.14% from their previous position, valued at approximately $0.85 million.
-
Prior Goldman Sachs Reduction
On January 9, 2026, Goldman Sachs had reported a temporary reduction in its total stake to 3.68% from a previous 5.27%, valued at approximately $8.66 million.
Analysis
The filing indicates a notable increase in institutional ownership for Evotec SE. The Goldman Sachs Group, Inc. reported a significant increase in its total stake to 6.12% as of January 13, 2026, primarily through instruments. This latest move represents a substantial acquisition, following a temporary reduction earlier in January, and suggests renewed and stronger institutional confidence in the company. Additionally, Michael Kaufman and MAK Capital Fund LP also increased their combined stake to 5.17% on January 9, further contributing to a positive investor sentiment regarding the company's ownership structure.
At the time of this filing, EVO was trading at $3.43 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.2B. The 52-week trading range was $2.84 to $4.80. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.